ArticleScientific reports2025
Novel COL4A3-COL4A5 variants and digenic inheritance in pediatric Alport syndrome from Southwestern China.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: a novel non-canonical splice site variant in COL4A5 in a patient with Alport syndrome.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Alport syndrome is a hereditary glomerular disease driven by pathogenic variants in COL4A3-COL4A5 that compromise the α3-α4-α5 type IV collagen scaffold, manifesting as persistent hematuria, proteinuria, and ultimately end-stage renal disease. Its pronounced phenotypic variability, low sensitivity of renal biopsy, and limited response to ACE inhibitors complicate accurate diagnosis and therapy. In a cohort of 40 pedigrees from southwest China, we discovered 21 novel COL4A3-COL4A5 mutations. Notably, two families carried rare digenic COL4A4/COL4A5 variants, providing strong evidence for dual-locus pathogenicity. Immunofluorescence of five mutation-positive patients revealed allele-specific depletion of α3 and α5 chains in the glomerular basement membrane, with frameshift and splice-site mutations eliciting more severe collagen loss than missense. Complementary AlphaFold modeling predicted that digenic variants induce greater destabilization of Gly-X-Y triple helices domain than monogenic lesions. Over three years, ACEI therapy achieved only sporadic partial remissions, underscoring the need for precision-guided treatment strategies. This study not only expands the genetic spectrum of Alport syndrome in China's ethnic minority populations but also elucidates the mechanistic impact of digenic inheritance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.